Hinge Health price target raised to $57 from $46 at Morgan Stanley

Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Hinge Health (HNGE) to $57 from $46 and keeps an Overweight rating on the shares. Revenue growth and the forward trajectory cleared “a high bar” with a “solid beat and raise” report, the analyst tells investors. The firm is increasing its annual revenue estimates by 8% and its EBIT estimates are “more than doubling” in 2025 as the company “delivered exceptional incremental margins,” the analyst added.